Overview

Location [1]
9p21.3
Protein [2]
S-methyl-5'-thioadenosine phosphorylase
Synonyms [1]
DMSMFH, DMSFH, HEL-249, MSAP, c86fus, LGMBF, BDMF

MTAP is altered in 1.11% of all cancers with glioblastoma, breast invasive ductal carcinoma, lung adenocarcinoma, pancreatic adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations [3].

MTAP GENIE Cases - Top Diseases

The most common alterations in MTAP are MTAP Loss (4.92%), MTAP Amplification (1.28%), MTAP-RAF1 Fusion (0.04%), MTAP A191fs (0.05%), and MTAP A76V (0.04%) [3].

MTAP GENIE Cases - Top Alterations

Significance of MTAP in Diseases

Pancreatic Ductal Adenocarcinoma +

Urothelial Carcinoma +

Gastric Adenocarcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Malignant Solid Tumor +

Non-Small Cell Lung Carcinoma +

Head And Neck Squamous Cell Carcinoma +

Lymphoma +

Prostate Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.